Monday, September 14, 2026

Taemin’s New Mini-Album Phase 1: Soft Violence Set to Redefine K-Pop Aesthetics

Singer Taemin returns with a new mini-album PHASE 1: Soft Violence, showcasing an evolved aesthetic on August 31.

Axis of Evil Returns: Kim Challenges US With Hwasong-20 ICBMs and Russian Flag In Mass Military Show

North Korea celebrated its Workers' Party's 80th anniversary with a military parade, showcasing the new Hwasong-20 ICBM and close ties with Russia.

Netflix Investment Scandal: Director Carl Rinsch Sentenced to 30 Months for 11 Million USD Fraud

Filmmaker Carl Rinsch sentenced to 30 months for embezzling $11M from Netflix, misusing funds for personal luxury and investments.

Tag: CDMO

Samsung Biologics Launches 3 Billion USD Stock Offering to Acquire Polypeptide Group: What This Means for the Global CDMO Market

Samsung Biologics plans a 2.3 billion USD capital increase to become a top-tier CDMO, primarily for acquiring Polypeptide Group.

MediPost Signs CDMO Agreement With Qstem for Dermal Papilla Cell Culture Medium

MediPost will establish a commercial-scale production system for Qstem’s hiPSC-based dermal papilla cell culture medium, expanding its CDMO business beyond cell therapies.

Samsung Biologics Accelerates “Three-Pillar Expansion Strategy” With Peptide CDMO Acquisition to Drive Global Growth

Samsung Biologics acquires Polypeptide Group for $1.8 billion, expanding into the peptide CDMO market to enhance growth and capabilities.

Interview: Huons’ PanGen Bets on ‘Development-Focused CDMO’ Strategy Built on Biosimilar Experience

South Korea's PanGen CDMO emphasizes development expertise and tailored services, enhancing drug development support for clients.

Lotte Biologics’ ‘Three Production Batches, 14% Utilization’ Underscores Need for New Orders Over New Plants

Lotte Biologics aims to enter the global CDMO market by expanding production, but faces challenges in securing contracts and profitability.

Lotte Biologics says it has secured top-10 global CDMO manufacturing capacity [BIO USA]

Lotte Biologics is set to begin commercial production by the end of 2026, advancing its capabilities in the global CDMO market.

Is BTGEN the Next Big Player in Biopharmaceuticals? Discover Their Unique CDMO Strategy

BTGEN is expanding its CDMO business with National Growth Fund support, focusing on innovative processes instead of competing on scale.

ST Pharm Targets Next-Generation RNA Therapies, Positions Itself as Key CDMO Partner at BIO USA

The RNA therapeutics market is evolving, with ST Pharm aiming to lead in precision manufacturing and targeted delivery for next-gen therapies.

Matica Bio Launches Open Access Platform: A Game Changer for Gene Therapy in 2026

Matica Bio launches an open CDMO platform for gene therapy, enhancing client control and streamlining production with Cirsium Biosciences.

Boryung Begins First Global CDMO Supply of Alimta Through Taiwan Partnership

Boryung Pharmaceutical starts supplying Alimta to Lotus, enhancing global CDMO efforts and addressing chemotherapy drug shortages.

ST Pharm Expands Global CDMO Outreach at TIDES USA and ASGCT 2026

ST Pharm showcased its CDMO capabilities at TIDES USA and ASGCT 2026, focusing on nucleic acid therapeutics and strategic partnerships.

Samsung Biologics Strengthens Global Partnerships at Decat Week 2026: Key Insights and Strategies

Samsung Biologics aims to enhance global partnerships at J.P. Morgan's Healthcare Conference 2026, showcasing its CDMO strengths.

HLB Pep Signs Deal with Japan’s ReproCELL to Supply Customized Neoantigen Peptides — The Future of Precision Medicine?

HLB PEP partners with Reprocell to supply customized neo-antigen peptides for personalized cancer treatment, targeting global markets.

Estipam Secures Record 897 Billion KRW Contract for Oligonucleotide Raw Materials: What This Means for the Asian Market

ST Pharm secures a record 89.7 billion KRW contract for oligonucleotide ingredients, enhancing its global market position.

Top News

- Our Sponsors Ad -

Follow us